Dale Pfost-MicroBiome Therapeutics-A Drinkable Blend of Prebiotics to Feed Human Microorganisms and Boost Human Health
Finding Genius Podcast
Richard Jacobs
4.4 • 1K Ratings
🗓️ 25 September 2018
⏱️ 33 minutes
🧾️ Download transcript
Summary
During the past decade, the human microbiome has slowly come to be recognized as an integral factor of human health, one that's been misunderstood for far too long. Whether it's an autoimmune disorder, diabetes, habitual overeating, a central nervous system disorder, or irritable bowel syndrome, Dale Pfost believes there's a connection to be found with the microorganisms that live inside each and every one of us. With active research being conducted on this topic, his opinion is backed by evidence and shared by many.
Pfost now serves as the CEO of MicroBiome Therapeutics, a company founded nine years ago with the goal of bolstering the health of the microbiome in order to bolster the health of people. So, what's the main contributor to the health of the microbiome, and what do we need to do in order to address it? Pfost believes the number one problem is our diet, something which has changed dramatically over the past several decades; we're overeating, yet we're simultaneously underfeeding the microorganisms that enable us to live healthy lives.
What's the solution? The team at Microbiome Therapeutics has just launched BiomeBliss, a perfectly formulated blend of prebiotics designed to feed microorganisms the nutrients they need but often don't receive in sufficient amounts (if at all). Based on the most recent double-blind, randomized clinical studies, BiomeBliss has produced three results: satiety (absence of hunger), increased GI health, and lower glycemic indexes.
Tune in to learn more about this fascinating new area of research and what BiomeBliss can offer you, and reach out with questions via the website at mbiome.com.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Welcome to Almost Here, Around the Corner of Future Technology Podcasts with Richard Jacobs. |
| 0:07.0 | Future Technologies is to transform our lives for better or worse or the focus of this podcast. |
| 0:13.0 | Almost here means these technologies are now here and starting to be used. |
| 0:17.0 | Or just around the corner, for Bitcoin to artificial intelligence, |
| 0:21.0 | 3D printing, blockchain, virtual reality, and more. |
| 0:25.0 | Hello, this is Richard Jacobs with the Future Tech Podcast. |
| 0:30.0 | My guest today is Dale Post. |
| 0:32.0 | He's a CEO of Microbiome Therapeutics and they've just |
| 0:35.8 | launched what's called Biome Bliss. It's a gastrointestinal microbiome modulator that he's going to get |
| 0:42.3 | into the details of. So Dale, how you doing? |
| 0:44.6 | Very good. Thank you for having. Yeah. So tell me basically what's the premise of |
| 0:49.0 | a microbiome therapeutics and then we'll talk about biome lists after that? |
| 0:53.2 | So the microbiome is one of the most interesting areas in the biomedical sciences that has come |
| 0:58.5 | along in the last decade or so. |
| 1:01.1 | And it's the study of microorganisms inside and on our bodies and you know |
| 1:07.6 | historically over the last century or so people have thought that microbes are |
| 1:11.5 | bad and we've we've led to cleaner and |
| 1:15.0 | cleaner lives over the decades and now people have gone full circle and |
| 1:18.9 | recognize that the microorganisms inside our body aren't just an afterthought. |
| 1:23.3 | They're actually integral to our health. |
| 1:25.2 | And so we started a company nine years ago, |
| 1:27.4 | microbiome therapeutics, to focus on means |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Richard Jacobs, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Richard Jacobs and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.

